阜阳什么医院治痤疮的比较有效阜阳皮肤病去那家医院,阜阳市哪里可以治疗痘痘,阜阳治荨麻诊更好的医院,阜阳哪些医院治痘痘好,阜阳肥东医治痘痘哪里好,阜阳皮肤病专业在哪,阜阳治灰指甲去哪个医院比较好

The Cruise Lines International Association announced Monday new regulations for cruising in the Americas.The association, which represents major global cruise lines, said cruises could start back up soon "with support and approval of regulators and destinations.""We recognize the devastating impact that this pandemic, and the subsequent suspension of cruise operations, has had on economies throughout the world, including the nearly half a million members of the wider cruise community and small businesses in the Americas who depend on this vibrant industry for their livelihoods," CLIA president, CEO Kelly Craighead said in the press release. "Based on what we are seeing in Europe, and following months of collaboration with leading public health experts, scientists, and governments, we are confident that these measures will provide a pathway for the return of limited sailings from the U.S. before the end of this year."The new rules include everyone being tested for COVID-19 before embarking and mandatory mask-wearing for everyone onboard.Also, everyone must abide by physical distancing. There will be an increase of fresh air through the ventilation system, medical capability with risk-based response plans, and shore excursions must abide by cruise operators' prescribed protocols.The CLIA announced back in August that its ocean-going cruise line members will suspend their U.S. operations until at least Oct. 31. 1439

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The Centers for Disease Control and Prevention and the American Medical Association are working with the Ad Council to educate people about the flu vaccine, particularly in communities of color.“I understand. As an African American physician, I understand some of the mistrust and distrust,” said Dr. Patrice Harris with the American Medical Association.CDC data shows not enough people get the flu shot.People die unnecessarily and unvaccinated African Americans have twice the hospitalization rate due to flu.“And when we consider other things like diabetes, heart and lung disease, asthma and other conditions that can get exasperated in the presence of the flu, it’s particularly protective for people with those conditions,” said Dr. Leandris Liburd, CDC Associate Director for Minority Health.There's more than 50 years of data on the safety of the flu vaccine.There is the potential now for a “twindemic.”“And so, by taking care of our health, we are saying we care about our family members, our community members and we are taking care of their health as well,” said Harris.The CDC anticipates delivering nearly 200 million flu vaccine doses.CVS and Walgreens say they plan to give as much as double the amount of vaccines as they did last season.It takes about two weeks after vaccination for the body to be fully protected.Click here to learn where to get your vaccine. 1387

The delayed Tokyo Olympics could not be held next year if conditions surrounding the coronavirus pandemic continue as they are, the president of the organizing committee said Wednesday.In an interview with Japanese broadcaster NHK, Yoshiro Mori said he was hopeful the situation would improve and suggested a vaccine was the key.“If this kind of situation (with COVID-19) continues, is it possible to hold the games?” Mori was asked by NHK.“If current situation continues, we couldn’t,” Mori replied, speaking in Japanese.The Tokyo Olympics are scheduled to open on July 23, 2021 — a year from Thursday. A small, 15-minute ceremony without fans is scheduled for Thursday at the new national stadium to mark the date.The International Olympic Committee and Japanese organizers have repeatedly expressed confidence the games will take place, though they have offered few details on how they can happen in the middle of a pandemic.The IOC and organizers have also said the Olympics will not be postponed again and would be canceled.“It would be too much for us to answer each of these hypothetical questions,” Mori said. “I don’t think this situation will last for another year.”Researchers have said a vaccine could be six-to-nine months away, which Mori said was the key. Some, however, question if young athletes should be a priority, and if all would agree to be vaccinated.“Whether the Olympics can be done or not is about whether humanity can beat the coronavirus,” Mori said. “Specifically, to develop a vaccine or drug is the first point.”Organizers and the IOC say they want to simplify the games to help reduce the soaring costs. But officials cannot say now if fans will be permitted next year, or if athletes will face quarantines. They say few details will be available until the fall.Plans call for the full contingent of 11,000 Olympic athletes and 4,400 Paralympic athletes to be competing at 42 venues.About 1,000 deaths in Japan have been attributed to the coronavirus. Tokyo has seen a rising number of daily cases in the last few weeks, which reached a high of almost 300 last week.But the numbers are relatively modest for a metropolitan area of 14 million.___More AP sports: https://apnews.com/apf-sports and https://twitter.com/AP_Sports 2265

The former police officer who knelt on the neck of George Floyd prior to Floyd's death in May has been released on bail, according to WCCO-TV and The Washington Post.Bail in his case had been set at .25 million, or million with conditions, according to WCCO. NBC News reports that Chauvin's release was conditional.Chauvin has been charged with second-degree murder, third-degree murder and manslaughter in connection with Floyd's death.Three other former police officers — J. Alexander Kueng, Thomas Lane and Tou Thao — face charges of aiding and abetting murder and manslaughter.Floyd's death sparked nationwide protests against systemic racism and police brutality across the country throughout the summer.Ben Crump, a civil rights attorney who has been working with the Floyd statement, decried Chauvin's release. ”Derek Chauvin’s release on bond is a painful reminder to George Floyd’s family that we are still far from achieving justice for George," Crump said in a statement. "The system of due process worked for Chauvin and afforded him his freedom while he awaits trial. In contrast, George Floyd was denied due process, when his life was ended over a bill. There was no charge, no arrest, no hearing, no bail. Just execution. Although George Floyd was denied justice in life, we will not rest until he is afforded full justice in death. The civil litigation team looks forward to our day in court.” 1426